Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study
about
Sertraline and breastfeeding: review and meta-analysisMetabolism of BYZX in human liver microsomes and cytosol: identification of the metabolites and metabolic pathways of BYZXEffects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice.Sucralose, a synthetic organochlorine sweetener: overview of biological issuesEffect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertralineThe pharmacokinetics of sertraline in overdose and the effect of activated charcoal.A novel algorithm for analyzing drug-drug interactions from MEDLINE literature.Sertraline for the treatment of depression in Alzheimer disease: genetic influences.Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics.The impact of CYP allelic variation on antidepressant metabolism: a review.Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseasesAmine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans: has the involvement of amine oxidases been neglected?Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors.Induction effects of ritonavir: implications for drug interactions.Drug interaction in psycho-oncology: antidepressants and antineoplastics.Psychotropic drug-drug interactions involving P-glycoprotein.Fetal serotonin reuptake inhibitor antidepressant exposure: maternal and fetal factors.Evaluation of the pharmacokinetics, safety and clinical efficacy of sertraline used to treat social anxiety.Monoamine oxidase A and B substrates: probing the pathway for drug development.Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition.Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?Fan the flame: trazodone-induced mania in a unipolar depressed patient with stable sertraline treatment.Sertraline inhibits the transport of PAT1 substrates in vivo and in vitro.Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans.Role of physiological intestinal water in oral absorption.Metabolism, pharmacokinetics and excretion of the GABA(A) receptor partial agonist [(14)C]CP-409,092 in rats.Time-dependent inhibition of CYP3A4 by sertraline, a selective serotonin reuptake inhibitor.Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers.Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome.SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study.Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances.Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients.Analysis of sertraline in postmortem fluids and tissues in 11 aviation accident victims.Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model.Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers.Uptake and metabolism of the antidepressants sertraline, clomipramine and trazodone in a garden cress (Lepidium sativum) model.Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims.Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.
P2860
Q28080470-226D29DC-8EC2-4669-91F5-779152BBE882Q28485860-550FFADC-101C-49F9-89BA-E025609AC60FQ34217306-C30E0092-16AA-447E-A3B6-272CAC579C4AQ34657381-0141105D-459F-4A41-807C-4A03AE9291D4Q34978292-ADDFE30A-60F8-4528-B5D4-7F48A23D7C91Q35023742-27BC9969-F8E7-4CD2-9991-EE834C343C21Q36323871-E0EAC053-0606-4BD4-B368-E5D38F8A7E8EQ36503660-B6799AE7-0F5E-4CD7-A4B1-8FDBF182C5C3Q36662870-77478DC2-A33E-40D0-AB30-E4E3C5B3E0EEQ36725210-301D8746-ACFD-4CA2-9C1B-3FC3E23019E0Q36733922-B95AF84C-85E2-44D9-9E3A-145D049AD38BQ36941961-5DAB8892-6F83-47F7-B500-B2F8B8A40E4CQ37037060-161F5C51-84BC-4673-A28E-05CBD3048AFFQ37199533-DA62F8A8-0EFF-4A31-AB67-84495A5C78E9Q37962101-04FA2F38-87F9-4B45-95BE-30265C2B4FF2Q38047816-21D086C3-8631-4B91-9C0F-D330269BDF8FQ38052726-19F0E63D-55E4-4195-90EE-CD5EE1EF67C9Q38120061-FC9AB875-7B21-4518-A633-7CB34D57B52AQ38217505-878CC195-1049-42FB-AB5A-40C268DAA88FQ38509732-F889D8F1-C696-4E0C-94C4-35760979804AQ38678838-4A136254-6E13-4507-9A8A-C99B1F71E96BQ38958223-B475E402-8479-413C-BA0F-7E8B40C0087BQ41561493-3177CEB4-7F4C-4D8A-A4EC-C8E32A3D2A86Q41882651-5A9515E3-F2FC-45BE-AF0E-28BB1C4C71D9Q41889718-272FFB65-8179-4890-82CA-663B3CD2199AQ43117344-4751CAD9-7F4D-441C-807D-0C9C895E89FDQ43119943-FE170A0B-9FB9-48AD-816B-47269A2FB601Q44552525-AF196FE9-9542-414E-9892-571D50FDB731Q46145193-E12B799E-BF7B-4C37-954A-677EED0DB334Q46227616-2FA34A5A-C6B8-4D45-A962-4E4F2EB828A5Q46466970-55602899-1E18-4DC8-8A7A-3996332D8787Q46672840-85DA7CA1-C832-453C-9CCB-364AEE6157AAQ47899552-C450E15B-E926-419E-BD89-829DE17F912EQ48118637-68FFF988-3EE7-41E3-A149-2695A2FF9A10Q48500206-CB2ED938-CD7E-462F-823F-29EFE1234ED8Q49345918-588F0536-06C6-4998-AF9C-157678F10C2DQ50026018-69C9FB63-A789-45D1-9331-9941391BECA3Q50050155-5A40897E-5406-4009-B844-74CB989E06F7Q50521741-A107D2C4-EEEA-4AAD-9DE3-D2D71E44DEA3Q51928851-9EF5222E-640D-4EAE-80AE-F64194320163
P2860
Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Sertraline is metabolized by m ...... es in human: an in vitro study
@ast
Sertraline is metabolized by m ...... es in human: an in vitro study
@en
Sertraline is metabolized by m ...... es in human: an in vitro study
@nl
type
label
Sertraline is metabolized by m ...... es in human: an in vitro study
@ast
Sertraline is metabolized by m ...... es in human: an in vitro study
@en
Sertraline is metabolized by m ...... es in human: an in vitro study
@nl
prefLabel
Sertraline is metabolized by m ...... es in human: an in vitro study
@ast
Sertraline is metabolized by m ...... es in human: an in vitro study
@en
Sertraline is metabolized by m ...... es in human: an in vitro study
@nl
P2093
P3181
P356
P1476
Sertraline is metabolized by m ...... es in human: an in vitro study
@en
P2093
Larry M Tremaine
Loretta M Cox
R Scott Obach
P304
P3181
P356
10.1124/DMD.104.002428
P407
P577
2005-02-01T00:00:00Z